Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of ATR-002 in Healthy Subjects
NCT04385420Phase 1Completed
- Sponsor
- Atriva Therapeutics
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Zapnometinib in influenza (9 arms), sponsored by Atriva Therapeutics. Primary endpoint: Treatment-emergent adverse events. Started Apr 2019; status: completed.
02
Drugs
Zapnometinib
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04385420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385420.